Other key assumptions After the end of treatment, we assume that it will take 3 y for treatment responders to return to their original weight, that is, the weight they had before the beginning of treatment. In the model, orlistat nonresponders are allocated the weight loss associated with placebo nonresponders because the model assumed orlistat nonresponders stopped treatment after 3 months. This differed from the clinical trial where treatment continued, irrespective of response. We assumed three capsules of orlistat were taken daily which is generous since, on average, patients take 2–2.5 per day. We calculated only the cost savings associated with the reduction in T2DM and, not the reduction in dyslipidaemia and / or hypertension.